Table 1.
Characteristics of Human Immunodeficiency Virus Patients in the IeDEA Collaboration Who Reengaged in Antiretroviral Therapy, According to Whether Postreengagement CD4 Cell-Count Measurements Were Available, East Africa, 2001–2011a
| Availability of CD4 Cell-Count Data After Reengagement in ART | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | CD4 Data Available(n = 8,501) | CD4 Data Not Available (n = 2,460) | Total (n = 10,961) | P Value | ||||||
| No. | % | Median (IQR) | No. | % | Median (IQR) | No. | % | Median (IQR) | ||
| Sex | 0.883 | |||||||||
| Female | 5,636 | 66.3 | 1,627 | 66.1 | 7,263 | 66.3 | ||||
| Male | 2,865 | 33.7 | 833 | 33.9 | 3,698 | 33.7 | ||||
| Age at disengagement from care, years | 37.8 (32.0–44.7) | 37.6 (31.2–44.7) | 37.8 (31.9–44.7) | 0.017 | ||||||
| CD4 cell count at ART initiation, cells/μL | 139.0 (67.0–208.1) | 138.0 (58.0–217.8) | 139.0 (64.0–210.0) | 0.244 | ||||||
| CD4 cell count available at disengagement | 1,826 | 21.5 | 772 | 31.4 | 2,598 | 23.7 | ||||
| CD4 cell count at disengagement (<2 months prior to last visit before disengagement), cells/μL | 293.5 (175.0–432.8) | 314.0 (136.0–495.2) | 297.0 (166.0–452.8) | 0.040 | ||||||
| CD4 cell-count measurements from reengagement to ART restart availablea | 3,985 | 36.4 | 0 | 0.0 | 3,985 | 36.4 | ||||
| CD4 cell count from reengagement to ART restarta, cells/μL | 248.0 (126.0–412.0) | N/A | 248.0 (126.0–412.0) | |||||||
| Time from ART initiation to disengagement, months | 12.9 (4.9–25.5) | 10.8 (3.4–23.0) | 12.5 (4.5–25.1) | <0.001 | ||||||
| Time from disengagement to reengagement, months | 2.7 (2.1–5.0) | 3.2 (2.2–7.1) | 2.7 (2.1–5.4) | <0.001 | ||||||
| Restart of ART | 8,156 | 95.9 | 2,131 | 86.6 | 10,287 | 93.9 | ||||
| ART restart at reengagement in care | 7,003 | 82.4 | 2,021 | 82.2 | 9,024 | 82.3 | ||||
| Time from disengagement to ART restart, monthsb | 2.9 (2.2–6.0) | 3.5 (2.2–9.6) | 3.0 (2.2–6.6) | <0.001 | ||||||
| No. of available CD4 measurements before disengagement | 2.0 (1.0–4.0) | 2.0 (1.0–3.0) | 2.0 (1.0–4.0) | <0.001 | ||||||
| No. of available CD4 measurements after reengagement | 2.0 (1.0–3.0) | N/A | 2.0 (1.0–3.0) | |||||||
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; IeDEA, East Africa International Epidemiology Databases to Evaluate AIDS; IQR, interquartile range; N/A, not applicable.
a The first available CD4 cell count up to 15 days after ART restart was considered.
b Values are expressed as median survival.